Viewing Study NCT07317102


Ignite Creation Date: 2026-03-26 @ 3:20 PM
Ignite Modification Date: 2026-03-31 @ 9:31 PM
Study NCT ID: NCT07317102
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-01-05
First Post: 2025-12-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)
Sponsor: Insulet Corporation
Organization:

Study Overview

Official Title: Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.
Detailed Description: Twelve-month, real-world, non-interventional, prospective follow-up of adult and pediatric patients aged more than 2 years old, prescribed the commercially available FreeStyle Libre 2 Plus configuration of the Omnipod 5 Automated Insulin Delivery System in France.

OPTIMAL-B study (Omnipod 5 - A French Prospective Multicentric Study in Real World), aims to provide the requisite real-world data on the glycemic control, quality of life, safety, and device usage profiles of users of the Omnipod 5 System during the 12 months after starting using Omnipod 5 in automated mode.

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: True
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: